Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, Inc., has renewed its collaborative agreement with the Centers for Disease Control and Prevention (CDC) to study RPI-78M and RPI-MN as a possible therapy for Rabies. RPI-78M is ReceptoPharm’s leading drug candidate for the treatment of autoimmune and neurological disorders and RPI-MN is ReceptoPharm’s leading antiviral drug candidate.

“This collaboration with the CDC allows us to analyze various formulas for both RPI-78M and RPI-MN as possible treatments for Rabies,” explained Paul Reid, CEO of ReceptoPharm. “Our goal with this study is to better understand the mechanism of action of our leading drug candidates and to determine their potential for treating advanced Rabies infections,” he concluded.

Rabies is a virus that infects the central nervous system and is characterized by inflammation in the brain (encephalitis). The virus is most often transmitted through the bite of a rabid animal, which commonly include raccoons, foxes and bats. Currently there is a post-exposure vaccination available to people exposed to rabies. If left untreated, Rabies is fatal. According to the World Health Organization, as many as 55,000 people worldwide die annually from Rabies infections.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The collaborative agreement with the CDC should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.